Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab +/- Fianlimab After SBRT in Oligo-Metastatic ccRCC
NCT07223541Phase 2Recruiting
- Sponsor
- University of Oklahoma
- Start
- Jan 2026
- Primary completion
- Aug 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of fianlimab in clear cell renal cell carcinoma (ccRCC), sponsored by University of Oklahoma. Started Jan 2026; status: recruiting.
02
Drugs
fianlimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07223541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223541.